tetano
Editor, Senior Moderator
Heart Rhythm. 2020 May 5. pii: S1547-5271(20)30422-7. doi: 10.1016/j.hrthm.2020.05.001. [Epub ahead of print]
Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management.
Siripanthong B[SUP]1[/SUP], Nazarian S[SUP]2[/SUP], Muser D[SUP]2[/SUP], Deo R[SUP]2[/SUP], Santangeli P[SUP]2[/SUP], Khanji MY[SUP]3[/SUP], Cooper LT Jr[SUP]4[/SUP], Chahal CAA[SUP]5[/SUP].
Author information
Abstract
Human coronavirus-associated myocarditis is known, and a number of COVID-19-related myocarditis cases have been reported. The pathophysiology of COVID-19-related myocarditis is thought to be a combination of direct viral injury and cardiac damage due to the host's immune response. COVID-19 myocarditis diagnosis should be guided by insights from previous coronavirus and other myocarditis experience. The clinical findings include changes in ECG, cardiac biomarkers, and impaired cardiac function. When cardiac MRI is infeasible, cardiac CT angiography with delayed myocardial imaging may serve to exclude significant coronary artery disease and identify myocardial inflammatory patterns. Because many COVID-19 patients have cardiovascular comorbidities, myocardial infarction should be considered. Where the diagnosis remains uncertain, an endomyocardial biopsy may help identify active cardiac infection through viral genome amplification and possibly refine the treatment risks of systemic immunosuppression. Arrhythmias are not uncommon in the COVID-19 patients; however, its pathophysiology is still speculative. Nevertheless, clinicians should be vigilant to provide prompt monitoring and treatments. The long-term impact of COVID-19 myocarditis, including in the majority of mild cases remains unknown.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Arrhythmias; Coronavirus disease 2019; Endomyocardial biopsy; Fulminant myocarditis; Interleukin-6; SARS-CoV-2
PMID:32387246DOI:10.1016/j.hrthm.2020.05.001
Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management.
Siripanthong B[SUP]1[/SUP], Nazarian S[SUP]2[/SUP], Muser D[SUP]2[/SUP], Deo R[SUP]2[/SUP], Santangeli P[SUP]2[/SUP], Khanji MY[SUP]3[/SUP], Cooper LT Jr[SUP]4[/SUP], Chahal CAA[SUP]5[/SUP].
Author information
Abstract
Human coronavirus-associated myocarditis is known, and a number of COVID-19-related myocarditis cases have been reported. The pathophysiology of COVID-19-related myocarditis is thought to be a combination of direct viral injury and cardiac damage due to the host's immune response. COVID-19 myocarditis diagnosis should be guided by insights from previous coronavirus and other myocarditis experience. The clinical findings include changes in ECG, cardiac biomarkers, and impaired cardiac function. When cardiac MRI is infeasible, cardiac CT angiography with delayed myocardial imaging may serve to exclude significant coronary artery disease and identify myocardial inflammatory patterns. Because many COVID-19 patients have cardiovascular comorbidities, myocardial infarction should be considered. Where the diagnosis remains uncertain, an endomyocardial biopsy may help identify active cardiac infection through viral genome amplification and possibly refine the treatment risks of systemic immunosuppression. Arrhythmias are not uncommon in the COVID-19 patients; however, its pathophysiology is still speculative. Nevertheless, clinicians should be vigilant to provide prompt monitoring and treatments. The long-term impact of COVID-19 myocarditis, including in the majority of mild cases remains unknown.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Arrhythmias; Coronavirus disease 2019; Endomyocardial biopsy; Fulminant myocarditis; Interleukin-6; SARS-CoV-2
PMID:32387246DOI:10.1016/j.hrthm.2020.05.001